Fig. 2From: Migraine induction with calcitonin gene-related peptide in patients from erenumab trialsQuestionnaire used for monoclonal antibody response stratification. Patients who reported excellent effect of treatment (efficacy score ≥ 50%) in at least two of the four outcome variables (i-iv) were defined as high responders. The remaining patients were defined as poor respondersBack to article page